These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 19564276

  • 1. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006.
    Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, Newburger JW.
    Pediatrics; 2009 Jul; 124(1):1-8. PubMed ID: 19564276
    [Abstract] [Full Text] [Related]

  • 2. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
    J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
    [Abstract] [Full Text] [Related]

  • 3. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 4. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
    J Rheumatol; 2004 Apr 17; 31(4):808-10. PubMed ID: 15088313
    [Abstract] [Full Text] [Related]

  • 5. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS, Durán DG, Peracaula CS, Iznardi CR, Tardío JO.
    An Pediatr (Barc); 2010 Nov 17; 73(5):268-71. PubMed ID: 20678974
    [Abstract] [Full Text] [Related]

  • 6. Kawasaki disease in a pediatric intensive care unit: a case-control study.
    Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glodé MP.
    Pediatrics; 2008 Oct 17; 122(4):e786-90. PubMed ID: 18809597
    [Abstract] [Full Text] [Related]

  • 7. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 17; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 8. Clinical features of patients with Kawasaki disease whose parents had the same disease.
    Uehara R, Yashiro M, Nakamura Y, Yanagawa H.
    Arch Pediatr Adolesc Med; 2004 Dec 17; 158(12):1166-9. PubMed ID: 15583102
    [Abstract] [Full Text] [Related]

  • 9. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
    Pediatrics; 2005 Dec 17; 116(6):e760-6. PubMed ID: 16322132
    [Abstract] [Full Text] [Related]

  • 10. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.
    Dale RC, Saleem MA, Daw S, Dillon MJ.
    J Pediatr; 2000 Nov 17; 137(5):723-6. PubMed ID: 11060542
    [Abstract] [Full Text] [Related]

  • 11. Kawasaki disease presenting as cervical lymphadenitis or deep neck infection.
    Kao HT, Huang YC, Lin TY.
    Otolaryngol Head Neck Surg; 2001 Apr 17; 124(4):468-70. PubMed ID: 11283510
    [Abstract] [Full Text] [Related]

  • 12. Arthritis presenting during the acute phase of Kawasaki disease.
    Gong GW, McCrindle BW, Ching JC, Yeung RS.
    J Pediatr; 2006 Jun 17; 148(6):800-5. PubMed ID: 16769390
    [Abstract] [Full Text] [Related]

  • 13. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
    O'connor MJ, Saulsbury FT.
    Clin Pediatr (Phila); 2007 May 17; 46(4):345-8. PubMed ID: 17475994
    [Abstract] [Full Text] [Related]

  • 14. [How does the time of diagnosis affect the course of disease in children with kawasaki syndrome? A retrospective analysis at one center].
    Raith W, Gamillscheg A, Heinzl B, Nagel BH, Koestenberger M, Beitzke A.
    Klin Padiatr; 2009 May 17; 221(2):83-8. PubMed ID: 19263328
    [Abstract] [Full Text] [Related]

  • 15. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
    Stenbøg EV, Windelborg B, Hørlyck A, Herlin T.
    Scand J Rheumatol; 2006 May 17; 35(4):318-21. PubMed ID: 16882598
    [Abstract] [Full Text] [Related]

  • 16. Epidemiological survey of Kawasaki disease in Sichuan province of China.
    Li XH, Li XJ, Li H, Xu M, Zhou M.
    J Trop Pediatr; 2008 Apr 17; 54(2):133-6. PubMed ID: 17965438
    [Abstract] [Full Text] [Related]

  • 17. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 17; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 18. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
    Pediatr Cardiol; 2003 Feb 17; 24(2):145-8. PubMed ID: 12457253
    [Abstract] [Full Text] [Related]

  • 19. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin.
    Shirley DA, Stephens I.
    Pediatr Infect Dis J; 2010 Oct 17; 29(10):978-9. PubMed ID: 20431427
    [Abstract] [Full Text] [Related]

  • 20. Recent developments and controversies in Kawasaki disease.
    Guzman-Cottrill JA, Shulman ST.
    Minerva Pediatr; 2004 Feb 17; 56(1):51-61. PubMed ID: 15249914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.